> It's incredibly relevant, why are GLP-1s less needed in Germany vs. US

Aside from whether the local healthcare coverage will pay for it, and the rate of GLP1 usage probably being proportional to the obesity rate, what is the basis for assuming there is disproportionately fewer people in Germany using these medications? Most people don't announce it.